Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Neutralizing Nogo Allows Spinal Cord to Rewire Correctly
30 August 2002. Neutralizing a growth inhibitor in the spinal cord allows the cord to respond to experimental damage by connecting axons from the cortex to their appropriate spinal cord targets, according to a report in the current issue of the Journal of Neuroscience.

When nervous system development is complete, the adult nervous system keeps a check on further axonal growth in the spinal cord with various proteins that inhibit neurite outgrowth, among them Nogo-A (formerly known as NI-250). A monoclonal antibody raised against Nogo-A, IN-1, has been shown to induce spinal cord neurite outgrowth in a number of previous studies.

In the present work, Florence Bareyre, Martin Schwab, and Brigitte Haudenschild of the University of Zurich in Switzerland examine the long-term effects of treating rats with IN-1, especially in conjunction with a lesion of the corticospinal tract (CST), the only direct pathway from the sensory and motor areas of the cortex to the spinal cord. IN-1 was delivered to the cortical neurons that give rise to the CST via antibody-producing cells injected directly into the brain.

Even without the CST lesion, the antibody induced new neurite outgrowth in the spinal cord. This sprouting was poorly directed, however, as sensory fibers entered areas reserved for motor connections and vice versa. Gene chip analysis of the spinal cord revealed that the antibody treatment led to an upregulation of growth factors (BDNF, VEGF), growth-related proteins (actin, myosin, GAP-43), and transcription factors (STATs).

When the CST on one side of the body was lesioned, cortical treatment with IN-1 antibody produced an initial random sprouting of spinal cord neurites across the midline from the intact CST, followed by a reorganization into the appropriate sensory and motor target areas. After six weeks, the newly sprouted motor fibers were still intact and had arborized extensively, though some of the new sensory connections had been lost. This process was accompanied by greater expression of guidance molecules (semaphorins and slits) and neurotrophic factors (BDNF, IGFs, BMPs). Understanding these gene expression changes will be important if researchers hope to use antibodies to effect long-term recovery from CNS lesions.-Hakon Heimer

Reference:Bareyre FM, Haudenschild B, Schwab ME. Long-lasting sprouting and gene expression changes induced by the monoclonal antibody IN-1 in the adult spinal cord. J Neurosci. 15 Aug 2002;22(16):7087-7110. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad